You are here

Reduction of Burn Progression and Scar Contracture with Cytokine-Neutralizing Gels

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH-13-C-0050
Agency Tracking Number: H122-016-0039
Amount: $150,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: DHP12-016
Solicitation Number: 2012.2
Timeline
Solicitation Year: 2012
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-03-05
Award End Date (Contract End Date): 2013-10-18
Small Business Information
6743 Wilkins Ave.
Pittsburgh, PA -
United States
DUNS: 803136758
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Newell Washburn
 President
 (412) 908-1309
 newell.washburn@gmail.com
Business Contact
 Newell Washburn
Title: President
Phone: (412) 908-1309
Email: newell.washburn@gmail.com
Research Institution
 Stub
Abstract

Washburn Therapeutics Inc. is developing biologically active gels that control inflammation by selectively neutralizing pro-inflammatory cytokines based on a technology being licensed exclusively by the company from Carnegie Mellon University. Preliminary results demonstrated that conjugates of antibodies against tumor necrosis factor-alpha and hyaluronic acid were able to reduce secondary necrosis in a partial-thickness rat burn model by 70%. This SBIR Phase I will focus on treating partial-thickness burns to test of the safety and efficacy of the technology in preventing extensive tissue necrosis following burn and measuring subsequent scar contraction in the rat burn model. The hypothesis of this research program is that prevention of burn progression through local control of inflammatory responses will improve healing outcomes. Early therapeutic intervention could make a significant impact in burn treatment.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government